Abstract
The goal is to reveal features of changes in the ratio of cytokines IL-1β, IL-6, TNF-α and IL-10 in blood depending on polymorphism of genes IL1В, IL6, TNFА and IL10 at different clinical forms of chronic inflammation of the middle ear in the stage of exacerbation before treatment and on the 10th day of treatment. Materials and methods. A total of 299 patients (129 men and 170 women) with chronic purulent otitis media were examined: 146 with tubotympanic form and 153 with epitympanoantral form. The control group included 183 relatively healthy donors, comparable to those of 299 patients by sex and age. Human genomic DNA was isolated from the blood by a standard method and was analyzed with the use of the polymerase chain reaction (PCR) in real-time. The concentration of cytokines IL-1β, IL-6, TNF-α and IL-10 in blood was measured by solid-phase enzyme-linked assay before and after 10 days of treatment. Statistical processing of the obtained data was performed using software package STATISTICA 6.0 (StatSoft Inc., USA). The critical level of significance when testing statistical hypotheses was taken to be less than 0.05. Results. In patients with chronic purulent otitis media, an increase in the concentration of IL-1β, IL-6 and TNF-α in the blood varies depending on polymorphism of genes IL1В (-3953, -511, -31), IL6 (-174), TNFА (-308) and the clinical form of the disease. The concentration of IL-10 in the blood depends more on the polymorphism of the IL10 gene (-1082, -592) than on the clinical form of the disease. The combined increase of concentration of IL-10 and proinflammatory cytokines in the blood before the beginning and on the 10th day of combined treatment of patients with tubotympanic and epitympanoantral forms of chronic purulent otitis media, in carriers of high-producing alleles inflammatory cytokines of polymorphic variants of genes IL1B, IL6 and TNFA, indicates a genetic predisposition to hyperergic the course of inflammation.
Highlights
The goal is to reveal features of changes in the ratio of cytokines IL-1β, IL-6, TNF-α and IL-10 in blood depending on polymorphism of genes IL1В, IL6, TNFА and IL10 at different clinical forms of chronic inflammation of the middle ear in the stage of exacerbation before treatment and on the 10th day of treatment
In patients with chronic purulent otitis media, an increase in the concentration of IL-1β, IL-6 and TNF-α in the blood varies depending on polymorphism of genes IL1В (-3953, -511, -31), IL6 (-174), TNFА (-308) and the clinical form of the disease
The concentration of IL-10 in the blood depends more on the polymorphism of the IL10 gene (-1082, -592) than on the clinical form of the disease
Summary
Цель – выявить особенности изменений соотношения цитокинов IL-1β, IL-6, TNF-α и IL-10 в крови в зависимости от полиморфизма генов IL1В, IL6, TNFА и IL10 при разных клинических формах хронического гнойного воспаления среднего уха в стадии обострения до и на 10-е сут лечения. У больных ХГСО повышение концентрации IL-1β, IL-6 и TNF-α в крови варьирует в зависимости от носительства полиморфных вариантов их генов (IL1В в локусах -3953, -511, -31, IL6 в локусе -174 и TNFА в локусе -308) и клинической формы заболевания. Цель исследования – выявить особенности изменений соотношения цитокинов IL-1β, IL-6, TNF-α и IL-10 в крови в зависимости от полиморфизма генов IL1В, IL6, TNFА и IL10 при разных клинических формах хронического гнойного воспаления среднего уха в стадии обострения до и на 10-е сут лечения
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
